Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Xinping Chen, Eric D. Austin, Megha Talati, Joshua P. Fessel, Eric H. Farber-Eger, Evan L. Brittain, Anna R. Hemnes, James E. Loyd, James West. Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016

Member's Comments

No comment yet.

Related content which might interest you: Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018 Year: 2019 NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Targeting cell motility in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 531-544 Year: 2013 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity Source: Eur Respir J, 55 (6) 1901228; 10.1183/13993003.01228-2019 Year: 2020 MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Renal dysfunction correlates with impaired hemodynamics and unfavorable outcome in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010